Inventiva, a biopharmaceutical company specializing in treatments for metabolic dysfunction-associated steatohepatitis (MASH), has announced a temporary trading halt for its ordinary shares on Euronext Paris, effective June 2, 2026, from 9:00 a.m. CEST. This decision was made at the company's request in anticipation of a forthcoming financing transaction, the specifics of which will be disclosed in a subsequent announcement. Trading is expected to resume on the same day at approximately 3:30 p.m. CEST, coinciding with the anticipated start of trading for American Depositary Shares (ADS) on the Nasdaq Global Market under the ticker symbol "IVA". Inventiva is currently conducting a pivotal Phase 3 clinical trial for its drug candidate lanifibranor, aimed at treating adult patients with MASH, a progressive liver disease. The company is publicly listed on both Euronext Paris and the Nasdaq.